Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. staphimpact

StaphIMPACT SIGNED

SA.100: Next-generation targeted antibacterial product entering European market

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 StaphIMPACT project word cloud

Explore the words cloud of the StaphIMPACT project. It provides you a very rough idea of what is the project "StaphIMPACT" about.

alternatives    contribution    secured    claiming    million    resistant    markets    world    extra    infections    health    7    8b    aureus    prepares    2050    netherlands    deaths    wound    bacteria    cagr    care    license    clinical    compounds    cosmetics    humanity    final    expressed    kols    smei    10    capacity    roll    thousands    syndrome    trillion    hyper    ideas    replace    rosacea    kills    people    employment    2024    according    develops    diabetic    changing    triggered    facilities    soft    profitability    caused    antibiotics    1    owns    ip    company    market    19    driving    acne    cancer    produces    kill    mrsa    dermatology    pharma    2018    inflammatory    sa    177b    micreos    ige    full    resistance    first    regardless    eczema    aggravated    small    companies    brand    us    endolysin    chosen    suffering    biggest    threats    launched    innovation    antibacterial    skin    staphylococcus    stakeholders    helping    life    time    unless    gladskin    2023    communication    antibiotic    100    indications   

Project "StaphIMPACT" data sheet

The following table provides information about the project.

Coordinator		 MICREOS HUMAN HEALTH BV 

Organization address
address: BANKAPLEIN 2
city: S GRAVENHAGE
postcode: 2585EV
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Netherlands [NL]
 Total cost 3˙565˙625 €
 EC max contribution 2˙495˙937 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MICREOS HUMAN HEALTH BV NL (S GRAVENHAGE) coordinator 2˙495˙937.00

Map

 Project objective

According to the WHO, antibiotic resistance is one of humanity’s biggest health threats, claiming ~10 million extra deaths per year and US$100 trillion by 2050, unless alternatives to antibiotics are developed. Micreos has developed the world’s first targeted antibacterial products, set to replace antibiotics. With its endolysin technology, for the first time it is possible to kill only the unwanted bacteria, regardless of resistance. Micreos’ endolysin technology was chosen as Europe’s most relevant Innovation 2018 (Ideas from Europe). Its first lead endolysin, SA.100, kills only Staphylococcus aureus, including the resistant MRSA. Soft-launched under the Gladskin brand in the Netherlands, it’s having life-changing impact for thousands of people with inflammatory skin conditions caused or aggravated by S. aureus, including eczema, acne, rosacea and Hyper IgE syndrome. Micreos also develops products for diabetic wound infections and a skin cancer triggered by S. aureus. Micreos owns all relevant IP and know-how on its technology and produces its compounds and Gladskin products at small-scale at its facilities in the Netherlands. With this SMEi, Micreos prepares for full roll-out into the EU markets of its SA.100/Gladskin. This includes scale-up of production capacity, strengthening clinical evidence and communication of results to KOLs and relevant stakeholders. Leading pharma and cosmetics companies have expressed interest to in-license Micreos’ technology for particular indications. Relevant markets are the consumer’s skin care market ($177b by 2024; CAGR 4.7%) and dermatology market ($19.8b by 2023; CAGR 9.1%.). Own contribution by Micreos for this SMEi is already secured. This SMEi enables Micreos to take final steps for EU-wide roll-out, driving employment growth and company profitability, and helping people suffering from inflammatory skin conditions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STAPHIMPACT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STAPHIMPACT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

AMBRPAY (2019)

Decentralized subscription payments with cryptocurrency

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More